GZ17-6.02 Inhibits the Growth of EGFRvIII+ Glioblastoma

Epidermal Growth Factor Receptor (EGFR) is amplified in over 50% of glioblastomas and promotes tumor formation and progression. However, attempts to treat glioblastoma with EGFR tyrosine kinase inhibitors have been unsuccessful thus far. The current standard of care is especially poor in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Justin, Bordeaux, Zachary A., McKeel, Jaimie, Nanni, Cory, Sutaria, Nishadh, Braun, Gabriella, Davis, Cole, Miller, Meghan N., Alphonse, Martin P., Kwatra, Shawn G., West, Cameron E., Kwatra, Madan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030248/
https://www.ncbi.nlm.nih.gov/pubmed/35456993
http://dx.doi.org/10.3390/ijms23084174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9030248/
https://www.ncbi.nlm.nih.gov/pubmed/35456993
http://dx.doi.org/10.3390/ijms23084174

Ejemplares similares